For example, Ricciuti et al. (2022) found a positive association with outcomes in 57% of patients with NSCLC under PD1/PD-L1 treatment who had both high TMB and high PD-L1 [37]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.